Cargando…
Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression
A tumour grows when the total division (birth) rate of its cells exceeds their total mortality (death) rate. The capability for uncontrolled growth within the host tissue is acquired via the accumulation of driver mutations which enable the tumour to progress through various hallmarks of cancer. We...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886869/ https://www.ncbi.nlm.nih.gov/pubmed/31738747 http://dx.doi.org/10.1371/journal.pcbi.1007493 |
_version_ | 1783474941803364352 |
---|---|
author | Anttila, Jani V. Shubin, Mikhail Cairns, Johannes Borse, Florian Guo, Qingli Mononen, Tommi Vázquez-García, Ignacio Pulkkinen, Otto Mustonen, Ville |
author_facet | Anttila, Jani V. Shubin, Mikhail Cairns, Johannes Borse, Florian Guo, Qingli Mononen, Tommi Vázquez-García, Ignacio Pulkkinen, Otto Mustonen, Ville |
author_sort | Anttila, Jani V. |
collection | PubMed |
description | A tumour grows when the total division (birth) rate of its cells exceeds their total mortality (death) rate. The capability for uncontrolled growth within the host tissue is acquired via the accumulation of driver mutations which enable the tumour to progress through various hallmarks of cancer. We present a mathematical model of the penultimate stage in such a progression. We assume the tumour has reached the limit of its present growth potential due to cell competition that either results in total birth rate reduction or death rate increase. The tumour can then progress to the final stage by either seeding a metastasis or acquiring a driver mutation. We influence the ensuing evolutionary dynamics by cytotoxic (increasing death rate) or cytostatic (decreasing birth rate) therapy while keeping the effect of the therapy on net growth reduction constant. Comparing the treatments head to head we derive conditions for choosing optimal therapy. We quantify how the choice and the related gain of optimal therapy depends on driver mutation, metastasis, intrinsic cell birth and death rates, and the details of cell competition. We show that detailed understanding of the cell population dynamics could be exploited in choosing the right mode of treatment with substantial therapy gains. |
format | Online Article Text |
id | pubmed-6886869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-68868692019-12-13 Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression Anttila, Jani V. Shubin, Mikhail Cairns, Johannes Borse, Florian Guo, Qingli Mononen, Tommi Vázquez-García, Ignacio Pulkkinen, Otto Mustonen, Ville PLoS Comput Biol Research Article A tumour grows when the total division (birth) rate of its cells exceeds their total mortality (death) rate. The capability for uncontrolled growth within the host tissue is acquired via the accumulation of driver mutations which enable the tumour to progress through various hallmarks of cancer. We present a mathematical model of the penultimate stage in such a progression. We assume the tumour has reached the limit of its present growth potential due to cell competition that either results in total birth rate reduction or death rate increase. The tumour can then progress to the final stage by either seeding a metastasis or acquiring a driver mutation. We influence the ensuing evolutionary dynamics by cytotoxic (increasing death rate) or cytostatic (decreasing birth rate) therapy while keeping the effect of the therapy on net growth reduction constant. Comparing the treatments head to head we derive conditions for choosing optimal therapy. We quantify how the choice and the related gain of optimal therapy depends on driver mutation, metastasis, intrinsic cell birth and death rates, and the details of cell competition. We show that detailed understanding of the cell population dynamics could be exploited in choosing the right mode of treatment with substantial therapy gains. Public Library of Science 2019-11-18 /pmc/articles/PMC6886869/ /pubmed/31738747 http://dx.doi.org/10.1371/journal.pcbi.1007493 Text en © 2019 Anttila et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Anttila, Jani V. Shubin, Mikhail Cairns, Johannes Borse, Florian Guo, Qingli Mononen, Tommi Vázquez-García, Ignacio Pulkkinen, Otto Mustonen, Ville Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression |
title | Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression |
title_full | Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression |
title_fullStr | Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression |
title_full_unstemmed | Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression |
title_short | Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression |
title_sort | contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886869/ https://www.ncbi.nlm.nih.gov/pubmed/31738747 http://dx.doi.org/10.1371/journal.pcbi.1007493 |
work_keys_str_mv | AT anttilajaniv contrastingtheimpactofcytotoxicandcytostaticdrugtherapiesontumourprogression AT shubinmikhail contrastingtheimpactofcytotoxicandcytostaticdrugtherapiesontumourprogression AT cairnsjohannes contrastingtheimpactofcytotoxicandcytostaticdrugtherapiesontumourprogression AT borseflorian contrastingtheimpactofcytotoxicandcytostaticdrugtherapiesontumourprogression AT guoqingli contrastingtheimpactofcytotoxicandcytostaticdrugtherapiesontumourprogression AT mononentommi contrastingtheimpactofcytotoxicandcytostaticdrugtherapiesontumourprogression AT vazquezgarciaignacio contrastingtheimpactofcytotoxicandcytostaticdrugtherapiesontumourprogression AT pulkkinenotto contrastingtheimpactofcytotoxicandcytostaticdrugtherapiesontumourprogression AT mustonenville contrastingtheimpactofcytotoxicandcytostaticdrugtherapiesontumourprogression |